Lisa Henderson

Cameron Turtle, Chief Business Officer of Eidos Therapeutics, Robin Toft, Founder and CEO of The Toft Group Executive Search and Sabrina Johnson, President and CEO, Daré Bioscience join Pharm Exec editors to talk about the future of the life sciences executive.

Our latest rankings and report of the top 50 biopharma companies provides a nice springboard to the coverage we have in store for you in the year's second half.

Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Bipharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.

Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.

The lifeblood of our coverage are the many interviews we conduct with industry executives-and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.

Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer' connection and the shifts taking place in making patient-centric programs and tools more alive for patients.

That often-muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

How innovation growth has upped the pressure on China to compete globally, forcing upgrades in regulatory, quality, and standards.

Pharm Exec profiles Dr. Xiaobin Wu, an accomplished leader in helming China operations at big pharmas such as Pfizer and Bayer, who believes his recent jump to biotech as GM of China and president of BeiGene will deliver his most lasting legacy.

Green-lighting China as our coverage focus in the February issue wasn't without conflict or hesitation, but as our reporting of the nation's biopharma landscape shows, perseverance and growth many times go hand-in-hand.

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.

As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Examining the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.

With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing.

A common takeaway in our exploration of "Emerging Biopharma" appears to be that these companies are those that go beyond pure discovery-and put equal efforts into the pivot to potential commercialization.

Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.

While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.

My first gathering of Pharm Exec's Editorial Advisory Board was both an honor and a learning experience-about us, the industry, and maintaining our mission to the our readers.

Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.

Amid rapid shifts in technology and consumer engagement, Pharm Exec explores how new models in hiring and recruitment-along with the evolution of the C-suite-are reshaping biopharma’s talent path of the future.

Pharma's evolving landscape in recent years has created the need to recruit experts from outside of industry-and establish new pathways for traditional executive roles in the life sciences.

The role of the medical affairs professional in the biopharma hierarchy has grown considerably in recent years, but challenges remain in its accent to true strategic partner with the C-suite.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.